The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
ToppM.S., GökbugetN., ZugmaierG.Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol.2014; 32(36): 4134–4140.
2.
ToppM.S., KuferP., GökbugetN.Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol.2011; 29(18): 2493–2498.
3.
ToppM.S., GökbugetN., SteinA.S.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicenter, single-arm, phase 2 study. Lancet Oncol.2015; 16(1): 57–66.
KlingerM., BrandiC., ZugmaierG.Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood.2012; 119(26): 6226–6223.
6.
Von StackelbergA., ZugmaierG., HandgretingerR.A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood.2013; 122(21): 70.
7.
ToppM.S., GoekbugetN., ZugmaierG.Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts).2012; 120: Abstract 670.
8.
ToppM.S., ZugmaierG., GoekbugetN.CD19/CD3 bispecific antibody blinatumomab (MT-103) is highly effective in treatment of patients with minimal residual disease from chemotherapy-resistant B-precursor acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts).2010; 116: 174.
9.
SchlegelP., LangP., ZugmaierG.Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica.2014; 99(7): 1212–1219.
10.
ViardotA., GoebelerM., NoppeneyR.Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annu Meet Abstr.2011; 118(21): 1637.
11.
RobertC., RibasA., WolchokJ.D.Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomized dose-comparison cohort of a phase 1 trial. Lancet.2014; 384(9948): 1109–1117.
12.
HamidO., RobertC., DaudA.Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med.2013; 369(2): 134–144.
PatnaikA., KangS.P., TolcherA.W.Phase 1 study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract]. J Clin Oncol.2012; 30(15): 2512.
15.
RobertC., HamidO., RibasA.Updated clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in advanced melanoma [abstract]. Pigment Cell Melanoma Res.2013; 26(6): 993.
16.
GaronE.B., LeighlN.B., RizviN.A.Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract 8020]. J Clin Oncol.2014; 32(15 suppl): 5s.
17.
HamidO., RobertC., RibasA.Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL) [abstract 3000]. J Clin Oncol.2014; 32(15 suppl): 5s.
18.
RizviN.A., GaronE.B., PatnaikA.Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract 8007]. J Clin Oncol.2014; 32(15 suppl): 5s.
19.
RibasA., HodiF.S., KeffordR.Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanolma (MEL) [abstract LBA9000]. J Clin Oncol.2014; 32(15 suppl): 5s.
